Drug Trial Radar · NCT05701774
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Jan 31, 2023
Primary completion
Jan 12, 2026
Study completion Apr 29, 2026
Sponsor
- Lead sponsor
- Soleno Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.
Conditions
- Prader-Willi Syndrome
Interventions
DCCRDrug
Once daily oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of DCCR (adverse events. Safety analyses will be conducted in all subjects who receive at least one dose of DCCR in the C614 study. ( Adverse events)Time frame: Baseline to End of Study or until resolution of certain adverse events
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Soleno Clinical Site
Orange, California
Soleno Clinical Site
Palo Alto, California
Soleno Clinical Site
San Diego, California
Soleno Clinical Site
Gainesville, Florida
Soleno Clinical Site
Atlanta, Georgia
Soleno Clinical Site
Indianapolis, Indiana
Soleno Clinical Site
Bethesda, Maryland
Soleno Clinical Site
Boston, Massachusetts
Soleno Clinical Site
Lansing, Michigan
Soleno Clinical Site
Saint Paul, Minnesota
Soleno Clinical Site
Paterson, New Jersey
Soleno Clinical Site
Mineola, New York
Soleno Clinical Site
Columbus, Ohio
Soleno Clinical Site
Nashville, Tennessee
Soleno Clinical Site
Dallas, Texas
Soleno Clinical Site
Salt Lake City, Utah
Soleno Clinical Site
Seattle, Washington
Fulbourn Hospital
Cambridge, United Kingdom
Soleno Clinical Site
Glasgow, United Kingdom
Soleno Clinical Site
Hull, United Kingdom
Soleno Clinical Site
London, United Kingdom
Soleno Clinical Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.